Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

44 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human epidermoid carcinoma cell: Control (A431-P cells) vs. highly invasive subline (A431-III cells)

ABSTRACT: Transcriptional profiling of human epidermoid carcinoma cell comparing control A431-P cells with highly invasive subline A431-III cells No treatmentt, A431-P cells vs. A431-III cells. A431-P cells are used as a reference to invstigate A431-III cells.

ORGANISM(S): Homo sapiens

SUBMITTER: Ming-Ting Lee

PROVIDER: E-GEOD-47996 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

human epidermoid carcinoma cell: Control (A431-P cells) vs. highly invasive subline (A431-III cells)

Project description:Transcriptional profiling of human epidermoid carcinoma cell comparing control A431-P cells with highly invasive subline A431-III cells

2013-06-18 | GSE47996 | GEO

RNA-seq of TCF4 silencing in A431 cells

Project description:TCF4 was silenced in cutaneous squamous cell carcinoma of A431 cells, and detected the mRNA profiles compared to the negative control and blank control.

2019-07-06 | E-MTAB-7372 | biostudies-arrayexpress

Transcription profiling by array of human wild type and gefitinib-resistant A431 cancer cells

Project description:A431 wild-type (wt) cancer cell line is sensitive to treatment with EGFR tyrosine kinase inhibitors (TKIs). By culturing it chronically under gefitinib, it eventually becomes resistant (A431_GR cell). We know of a few proteins involved in this mechanism of drug resistance, but a cDNA exprssion array would add information to other genes that might be involved in this resistance mechanism. We used microarrays to identify the differences in the global gene expression between A431_wt (wild-type) cells and A431_GR cells. Experiment Overall Design: Total RNA was isolated from parental (wild-type) and GR (gefitinib-resistant) A431 cells using TRIzol reagent (Invitrogen, Carlsbad, CA), followed by RNeasy Mini Kit column purification (Qiagen, Valencia, CA) including an in column DNAse clean-up using RNAse-free DNAse Set (Qiagen). Synthesis of cRNA target, its hybridization to Human Genome U133 Plus 2.0 microarrays and scanning of those arrays was performed using Affymetrix GeneChip products and reagents in accordance with the manufacturerâs recommendations at the Vanderbilt Microarray Shared Resource.

2008-04-06 | E-GEOD-10696 | biostudies-arrayexpress

RNA-seq of A431 cell line after gefitinib treatment

Project description:RNA sequencing of A431 cell line samples before and after gefitinib treatment, at 0, 2, 6 and 24 hours, was performed in order to characterize the cell line's early and late response to this drug, and to compare against proteomics (mass spectrometry) characterization of the cell line using the same setup. These data were used in Branca et al., HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics., Nat Methods. 2014 Jan;11(1):59-62 (doi: 10.1038/nmeth.2732).

2016-12-01 | E-MTAB-5285 | biostudies-arrayexpress

Homo sapiens

Project description:human epidermoid carcinoma cell: Control (A431-P cells) vs. highly invasive subline (A431-III cells)

| PRJNA208618 | ENA

HiRIEFII proteomics and proteogenomics of A431 cells and five histologically normal tissues

Project description:High Resolution Isoelectric Focusing (HiRIEF) LC-MS was used to analyze samples from the human A431 cell line and also samples of histologically normal tissues. The high analytical depth afforded by HiRIEF permitted proteogenomics on these two sample sets (A431 cells and normal tissues). The A431 data was obtained from a time course experiment upon Gefitinib treatment (EGFR inhibition) of A431 cells with harvests at 2h, 6h and 24h after treatment as well of untreated cells. Isobaric tag labelling of peptide samples with TMT10plex was used. Biological triplicate controls (TMT channels 126, 127N, 127C), duplicate 2h (128N, 128C), duplicate 6h (129N, 129C) and triplicate 24h (130N, 130C, 131) samples were employed. The normal tissues data was obtained from two separate TMT10plex sets. TMT set1 was composed of 9 samples, all from different individuals, including three placenta samples (126, 127N, 127C) two liver samples (128N, 128C), two kidney samples (129N, 129C), two tonsil samples (130N, 130C), plus an internal pooled standard (131). TMT set2 was composed of 8 samples, all from different individuals, including one tonsil sample (126), two liver samples (127C, 128N), two kidney samples (128C, 129N), three testis samples (129C, 130N, 130C), plus an internal pooled standard (131). The internal pooled standard was made by combining equal aliquots of the tryptic peptide mixtures from each of the 17 tissue samples.

2018-01-19 | PXD006291 | Pride

Transcription profiling by array to investigate the effect of combined external beam radiotherapy (photon or carbon) and 131I-Cetuximab endoradiotherapy in A431 xenograft tumors in mice

Project description:Subcutaneous A431 tumors in the right hind limb of NCr nu/nu mice were treated with 5 daily fractions of external beam radiotherapy (2 Gy photon or 1 Gy carbon per fraction), a single fraction of 7.2 MBq 131Iodine-labelled Cetuximab intravenously or a combination of the two. Untreated tumors served as controls. Mice were sacrificed and tumor tissue collected for expression profiling 5 days after endoradiotherapy of 1 week after the last fraction of external beam radiotherapy.

2023-12-08 | E-MTAB-6515 | biostudies-arrayexpress

Expression data to parental A431 VS CD109 KO A431

Project description:Expression data to parental A431 VS CD109 KO A431

| PRJNA482298 | ENA

RNA-seq of A431 cells expressing control or ARID1A-targeting shRNAs

Project description:We examined gene expression level in A431 cells expressing control or ARID1A-targeting shRNAs to study the mechanism underlying the tumor suppressive effect of ARID1A.

2019-11-30 | GSE131132 | GEO

Xenograft mouse study in C57BL6/SCID mice using A431 cells

Project description:In this study four groups involving, Control arm, Rapamycin arm, Nimotuzumab arm and the Combination group were involved. Four tumors from each group was evaluated for microarray analysis they were the two largest and two smallest from each group. Agilent one-color experiment,Organism: Human ,Agilent-Custom Whole Genome Human 8x60k designed by Genotypic Technology Pvt. Ltd. (AMADID: 027114) , Labeling kit: Agilent Quick-Amp labeling Kit (p/n5190-0442) 4 groups: control, rapamycin, nimotuzumab, and rapamycin and nimotuzumab

2011-10-19 | E-GEOD-32333 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data